SYNERGY™

Everolimus-Eluting Platinum Chromium Coronary Stent System

The SYNERGY BP Stent is a new category of stent that works synergistically, emphasizing the suppression of neointimal growth at the arterial wall while promoting healing inside the vessel. It features the Synchrony™ Bioabsorbable Polymer Coating, which is applied only to the abluminal side of the stent to promote rapid endothelialization.2

1. Wilson GJ et al, Catheter Cardiovasc Interv. 2015.
2. Eppihimer M, PhD. Impact of Polymer Type and Location on Stent Thrombogenicity and Endothelial Cell Coverage. EuroPCR 2014.

 

Freedom from Long-Term Polymer Exposure

The polymer on the SYNERGY BP Stent is absorbed when it’s no longer needed, shortly after the drug is completely eluted at three months, providing early healing and freedom from long-term polymer exposure.1

It was designed to address the challenges associated with permanent polymer stents such as inflammation, neoatherosclerosis and late stent thrombosis.

Everolimus is still present in the tissue out to 120-days while polymer completes absorption

Synchronous Absorption1
Thinner stent struts also impact healing. Stents with thinner strut designs have been proven to heal faster than thicker strut stents.2 The SYNERGY BP Stent has ultra-thin 74 µm* struts, which have shown more rapid healing compared to thicker stent strut designs in clinical cases and in preclinical research.3,4

1. Wilson GJ et al, Catheter Cardiovasc Interv. 2015.
2. Soucy N, Feygin J et al, EuroIntervention. 2010 Nov;6(5):630-7
3. Presented by J. M. de la Torre, MD at EuroPCR 2014
4. Presentation by Kazuyuki Yahagi, MD; Michael Joner, MD; Renu Virmani, MD at TCT 2014.

*Strut thickness for small vessel model is 0.0029” (74μm), Workhorse model is 0.0031” (79μm) and large vessel is 0.0032” (81μm). Boston Scientific data on file.

 

Optimal Healing Shown Through Strut Coverage and Angioscopy

SYNERGY™ BP Stent has shown full stent strut coverage as early as 30-days in humans and showed 0% stent thrombosis in all of these OCT analyses.
Understanding Healing from 30 days – 6 months in All Comers patients
 
But the proof is in the quality of healing. Through angioscopy, we are able to detect the quality of neointimal coverage not seen by OCT. The SYNERGY BP Stent shows differentiated and improved healing.
Neointimal Coverage of Current Generation DES5
Angioscopic images of stented human vessel at 12 and 13 months
 
View the Quality of Vessel Healing Seen Through Angioscopy
* Image captured at 13-month follow-up
** Images captures at 12-month follow-up
1. Adapted from poster presentation on behalf of Ida Riise Balleby, MD at ACC2016.
2. Presented by J. M. de la Torre, MD at TCT 2014.
3. Adapted from presentation by Juan Granada, MD, at CRT 2015.
4. de la Torre Hernández JM, et al. Catheter Cardiovasc Interv. 2015: Online ahead of print.
5. Nakayoshi T, Ueno T, Sasaki K, et al. Differential angioscopic findings of neointimal coverage among first-, second-, and next generation drug eluting stents. Int J Cardiol. 2016;223:450-451. Images courtesy of Professor Ueno.

Real-World Studies

Real-World Studies

Low event rates in real-world studies

Button
Clinical Outcomes

Clinical Outcomes

Outstanding evidence across trials

Button
Clinical Program

Clinical Program

Trial data and ongoing research

Button
Top